A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 307-310

  Gardiner, Anne ^a   Parker, Helen ^b   Glide, Sharron ^a   Mould, Sarah ^a   Robinson, Hazel ^a   Tracy, Ian ^a   Stankovic, Tanja ^c   Oscier, David ^a   Strefford, Jon ^b  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

11q23 MDR; ATM screening; CLL; Diminished FISH signal; FISH; SNP array

Indexed keywords

ADULT; AGED; ARTICLE; ATM PROBE; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q22.3; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DELETION; GENE IDENTIFICATION; GENE LOSS; GENE MUTATION; GENE PROBE; GENETIC DISORDER; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; DNA PROBES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84855921326     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.002     Document Type: Article

References (14)

1. Juliusson G., Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 1990, 45:143-160.
2. Juliusson G., Gahrton G., Einhorn S., Liu Y., Oscier D.G., Chapman R. Chromosome abnormalities and RB1 gene deletions in chronic lymphocytic leukemia. Blood 1993, 82:1938-1939.
3. Stilgenbauer S., Liebisch P., James M.R., Schroder M., Schlegelberger B., Fischer K., et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-q23.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A 1996, 93:11837-11841.
4. Catovsky D., Richards S., Matutes E., Oscier D., Dyer M.J., Bezares R.F., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-239.
5. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376:1164-1174.
6. Gunn S.R., Hibbard M.K., Ismail S.H., Lowery-Nordberg M., Mellink C.H., Bahler D.W., et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 2009, 23:1011-1017.
7. Pfeifer D., Pantic M., Skatulla I., Rawluk J., Kreutz C., Martens U.M., et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007, 109:1202-1210.
8. Grubor V., Krasnitz A., Troge J.E., Meth J.L., Lakshmi B., Kendall J.T., et al. Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). Blood 2009, 113:1294-1303.
9. Gunnarsson R., Mansouri L., Isaksson A., Goransson H., Cahill N., Jansson M., et al. Array-based genomic screening at diagnosis and follow-up in chronic lymphocytic leukemia. Haematologica 2011, [Epub ahead of print].
10. ISCN: an international system for human cytogenetic nomenclature 2009, S Karger, Basel. L. Shaffer, M. Slovak, L. Campbell (Eds.).
11. Premstaller A., Oefner P.J. Denaturing high-performance liquid chromatography. Methods Mol Biol 2003, 212:15-35.
12. Best O.G., Gardiner A.C., Majid A., Walewska R., Austen B., Skowronska A., et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008, 22:1456-1459.
13. Austen B., Skowronska A., Baker C., Powell J.E., Gardiner A., Oscier D., et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007, 25:5448-5457.
14. Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.